Ask AI
ProCE Banner Activity

Current Biomarker Testing and Targeted Therapy Approaches for Pancreatic Cancer

Clinical Thought
In this commentary, review expert best practices in molecular testing and targeted therapy for patients with advanced pancreatic cancer.

Released: March 17, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Ipsen Biopharmaceuticals Inc

Faculty Disclosure

Primary Author

Rachna Shroff, MD, MS, FASCO

Chief, Division of Hematology/Oncology, UA COM-T
Associate Director of Clinical Investigations, UACC
Professor of Medicine
University of Arizona Cancer Center (UACC)
University of Arizona College of Medicine - Tucson (UA-COM-T)
Tucson, Arizona

Rachna Shroff, MD, has disclosed that she has received consulting fees from Agios/Clovis, Debiopharm, Exelixis, Incyte, Merck, QED Therapeutics, and Seattle Genetics and funds for research support from Exelixis, Merck, and Pieris/Taiho/Rafael.